Abstract 1260TiP
Background
Lung cancer is the leading cause of cancer-related deaths worldwide, with over 40% of patients diagnosed at stage IV, mainly due to difficulties in early detection. Although low-dose CT (LDCT) screening assists in early diagnosis, its high false-positive rate demands more accurate and minimally invasive biomarkers. In LDCT screening, about 5% of cases exhibit lung nodules with a 5% or higher risk of malignancy (Lung-RADS category 4); however, most are benign, with actual lung cancers representing only 0.6% of the total screened population. A diagnostic test is essential to avoid unnecessary invasive examinations and identify individuals at higher lung cancer risk. Other liquid biopsy approaches using restricted range of biomarkers have diagnostic limitations for early-stage cancers.
Trial design
We are recruiting participants aged between 50 and 80 years old who have a smoking history of at least 20 pack-years and are either current smokers or former smokers who quit within the past 15 years. Eligible individuals must have lung nodules identified on chest CT scans as Lung-RADS category 4B or 4X and be scheduled for a pathological diagnosis for lung cancer with TNM stage IA. Five participating hospitals are collecting whole blood (15mL) samples and sending them to a central laboratory, IMBdx. IMBdx is extracting cfDNA, performing quality control (QC), and assessing [1] whole-genome methylation patterns, [2] fragmentomics, and [3] copy number variations. The results will be integrated into a machine learning-based algorithm to establish a cancer signature ensemble (CSE) index as a 5-tier categorical indicator for differentiating malignant and benign nodules. A training set of 150 cases will be used to develop the CSE index, and its diagnostic performance will be validated in a validation set of 150 cases. The CSE index for lung cancer discrimination is expected to exhibit a sensitivity and specificity of 75% and 95%, respectively. The study's outcomes aim to reduce unnecessary CT follow-ups or invasive tissue sampling/surgery. Future research will explore its applicability as a screening test for non-smokers or individuals at lower lung cancer risk.
Clinical trial identification
Clinical Research Information Service of Korea (CRiS), Registration ID: KCT0007484.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Cancer Center Korea (HA22C0140000022).
Disclosure
J. Yoon: Financial Interests, Personal, Advisory Board: IMBdx. H. Kim, S.Y. Kim: Financial Interests, Personal, Full or part-time Employment: IMBdx. T. Kim: Financial Interests, Personal, Ownership Interest: IMBdx. All other authors have declared no conflicts of interest.
Resources from the same session
1807P - Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Presenter: Nobuaki Matsubara
Session: Poster session 14
1808P - Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m<sup>2</sup>) versus every 3 weeks (25 mg/m<sup>2</sup>) in the CABASTY phase III trial
Presenter: Stephane Oudard
Session: Poster session 14
1809P - Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Presenter: Nicole Brighi
Session: Poster session 14
1810P - Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
Presenter: Michael Morris
Session: Poster session 14
1811P - Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study
Presenter: Andre Fay
Session: Poster session 14
1813P - Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
Presenter: Andrew Laccetti
Session: Poster session 14
1814P - First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
Presenter: Anne-Laure Giraudet
Session: Poster session 14
1815P - Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1
Presenter: Elena Castro
Session: Poster session 14